Compare Abbott Laboratories (ABT) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Celsius Holdings, Inc. — how do they compare? Abbott Laboratories trades at $95.44 (market cap $166.94B), while Celsius Holdings, Inc. trades at $30.55 (market cap $8.10B). The key difference: Abbott Laboratories is far larger — about 20.6× Celsius Holdings, Inc.'s market cap, and Abbott Laboratories pays a 2.63% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| ABT | CELH | |
|---|---|---|
Market Cap | $166.94B | $8.10B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $64.86 |
52-Week Low | $82.57 | $27.75 |
Enterprise Value | $193.69B | $9.98B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Celsius Holdings (CELH) trades at $31.70, down 4.4% on the day, with strong analyst consensus (95.65% buy ratings) and a $53.11 price target. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.41 beating expectations of $0.29. Revenue growth is robust, projected at $3.0B for 2026, though net margins have compressed from 17.2% in 2023 to 4.29% in 2025. Technical indicators show a bullish moving average trend but neutral oscillators, with key resistance at $34.
The outlook remains positive driven by international expansion and functional beverage demand, but risks include margin pressure, ongoing legal investigations, and high valuation multiples. The stock offers significant upside to consensus targets if growth execution continues, though investor sentiment is tempered by near-term profitability concerns and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
